Document is current

Any future updates will be listed below

Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy

Crossref DOI link: https://doi.org/10.1186/s12885-017-3775-6

Published Online: 2017-11-23

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark